PACB Quote, Financials, Valuation and Earnings

Atossa Therapeutics, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of --. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.29, signalling downside risk potential of -5.94%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 648.85%. Given that Atossa Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.319, which suggesting that the stock is 131.863% more volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 0.950, suggesting its less volatile than the S&P 500 by 4.956%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are larger than Atossa Therapeutics, Inc. quarterly revenues of --. Pacific Biosciences of California, Inc.'s net income of -$38M is lower than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 4.73x versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Celldex Therapeutics, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of -7753.43%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.29, signalling downside risk potential of -5.94%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.14 which suggests that it could grow by 79.54%. Given that Celldex Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Celldex Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.319, which suggesting that the stock is 131.863% more volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.281%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are larger than Celldex Therapeutics, Inc. quarterly revenues of --. Pacific Biosciences of California, Inc.'s net income of -$38M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 4.73x versus 755.79x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiora Pharmaceuticals, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of 84.08%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.29, signalling downside risk potential of -5.94%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 411.63%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.319, which suggesting that the stock is 131.863% more volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.753, suggesting its less volatile than the S&P 500 by 175.254%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are larger than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Pacific Biosciences of California, Inc.'s net income of -$38M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 4.73x versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of -735.19%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.29, signalling downside risk potential of -5.94%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 147.59%. Given that Intellia Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.319, which suggesting that the stock is 131.863% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Pacific Biosciences of California, Inc.'s net income of -$38M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 4.73x versus 16.51x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.